A case of encephalitis in a juvenile rheumatoid arthritis patient treated with etanercept.
10.3345/kjp.2010.53.2.262
- Author:
Ah Reum KWON
1
;
Eun Jung PARK
;
Ki Hwan KIM
;
Dong Soo KIM
Author Information
1. Department of Pediatrics, Yonsei University College of Medicine, Severance Children's Hospital, Seoul, Korea. dskim6634@yuhs.ac.kr
- Publication Type:Case Report
- Keywords:
Etanercept;
Juvenile rheumatoid arthritis;
Encephalitis
- MeSH:
Anti-Bacterial Agents;
Arthritis, Juvenile Rheumatoid;
Brain;
Central Nervous System Infections;
Encephalitis;
Fever;
Headache;
Hospitalization;
Humans;
Immunoglobulin G;
Magnetic Resonance Imaging;
Methotrexate;
Preschool Child;
Receptors, Tumor Necrosis Factor;
Seizures;
Steroids;
Sulfasalazine;
Tumor Necrosis Factor-alpha;
Vomiting;
Etanercept
- From:Korean Journal of Pediatrics
2010;53(2):262-266
- CountryRepublic of Korea
- Language:English
-
Abstract:
Tumor necrosis factor-alpha (TNF-alpha) is a major proinflammatory cytokine involved in the pathophysiology of juvenile rheumatoid arthritis. Etanercept is an effective inhibitor of TNF-alpha and has shown a beneficial effect in patients with JRA. However, the most important cause of concern related to etanercept administration is infection. We report a case of encephalitis in a JRA patient receiving long-term treatment with etanercept. The patient was a 4-year-old boy with refractory JRA, and he received etanercept subcutaneously at a dose of 0.4 mg kg(-1) day(-1) twice a week for 14 months, along with non-steroidal anti-inflammatory drugs, methotrexate, oral steroids, and sulfasalazine. The patient presented with sudden fever, headache, vomiting, a generalized tonic seizure, and changes in mental status. We suspected a central nervous system infection, and simultaneously administered antibiotics, an antiviral agent, and steroids. After 2 days of hospitalization, his mental function returned to normal, and he showed no further seizure-like movements. Brain magnetic resonance imaging scan of the patient showed a multifocal cortical lesion on both sides of the temporoparietooccipital lobe, which indicated encephalitis. Although we were unable to identify the causative organism of encephalitis, we think that the encephalitis may be attributed to infection, and the use of etanercept may have increased the risk of severe infection. Therefore, etanercept was discontinued and the patient recovered shortly after. To the best of our knowledge, this is the first case of encephalitis in a juvenile rheumatoid arthritis patient treated with etanercept.
